8. Tien Y, Lee C, Huang C, Hu R, Lee P. Surgery for gastrointestinal stromal tumors of the duodenum. Ann Surg Oncol. 2010 Jan; 17(1): p. 109-14.
9. Sampath S, Schultheiss T, Ryu J. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2010; 76: p. 728-734.
10. Hensley M, Ishil N, Soslow R. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009; 112: p. 563-567.
24. Chi D. National Organization for Rare Disorders.; 2018. https://rarediseases.org/rare-diseases/uterine-leiomyosarcoma/
34. Brennan M, Antonescu C, Alektiar K, Maki R. Management of Soft Tissue Sarcoma. 2nd ed. Switzerland: Springer; 2016.
35. Hensley M, Wathen K, Maki R. Adjuvant treatment of high-risk primary uterine leio- myosarcoma with gemcitabine/docetaxel, followed by doxorubicin: results of phase II multi- center trial SARC005. J Clin Oncol. 2010; 28.
36. Demetri G, Chawla S, VonMehren M. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracy- clines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009; 27: p. 4188-96.
37. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol. 2001 Oct; 12(10): p. 1423-32.
38. Hardman M, Roman JBA, Santin A. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol. 2007; 110: p. 518-520.